Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) Based Macrocyclic Chelator for 89Zr4+ and Its Use for ImmunoPET Imaging of HER2 Positive Model of Ovarian Carcinoma in Mice

A novel octadentate 3-hydroxypyridin-2-one (2,3-HOPO) based di-macrocyclic ligand was evaluated for chelation of Zr-89; subsequently, it was used as a bi-functional chelator for preparation of Zr-89-labeled antibodies. Quantitative chelation of Zr-89(4+) with the octadentate ligand forming (ZrL)-Zr-89 complex was achieved under mild conditions within 15 minutes. The Zr-89-complex was stable in vitro in presence of DTPA, but a slow degradation was observed in serum. In vivo, the hydrophilic Zr-89-complex showed prevalently renal excretion; and an elevated bone uptake of radioactivity suggested a partial release of Zr-89(4+) from the complex. The 2,3-HOPO based ligand was conjugated to the monoclonal antibodies, HER2-specific trastuzumab and an isotypic anti-gD antibody, using a p-phenylene bis-isothiocyanate linker to yield products with an average loading of less than 2 chelates per antibody. Conjugated antibodies were labeled with Zr-89 under mild conditions providing the PET tracers in 60-69% yield. Despite the limited stability in mouse serum; the PET tracers performed very well in vivo. The PET imaging in mouse model of HER2 positive ovarian carcinoma showed tumor uptake of Zr-89-trastuzumab (29.2 +/- 12.9 % ID/g) indistinguishable (p = 0.488) from the uptake of positive control Zr-89-DFO-trastuzumab (26.1 +/- 3.3 % ID/g). In conclusion, the newly developed 3-hydroxypyridin-2-one based di-macrocyclic chelator provides a viable alternative to DFO-based heterobifunctional ligands for preparation of Zr-89-labeled monoclonal antibodies for immunoPET studies.